Program
Aripiprazole
Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.
Drug pageAripiprazole: every studyMany companies study it; this page follows only the 124 they lead. All 292 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 1120 open or running | phase 4since Mar 26, 2004 | May 7, 2002 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 4since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Abdi İbrahim Otsukaits history only | 10 open or running | phase 4since Feb 23, 2016 | Feb 23, 2016 | none ahead |
| Chengdu Kanghong Pharmaceutical Groupits history only | 10 open or running | no phasesince Jul 24, 2017 | Jul 24, 2017 | none ahead |
| CMG Pharmaceuticalits history only | 10 open or running | phase 1since Jun 4, 2015 | Jun 4, 2015 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | no phasesince Mar 23, 2026 | Mar 23, 2026 | Sep 5, 2027NCT07547384 |
| Genovate Biotechnologyits history only | 10 open or running | phase 4since Oct 8, 2007 | Oct 8, 2007 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| H. Lundbeckits history only | 10 open or running | phase 3since Oct 7, 2013 | Oct 7, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences, Covance and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2011First study: phase 1 study in Depressive DisorderFirst studyNCT01424449 · 7 enrolled · United Kingdom
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brexpiprazolerule | Otsuka | phase 4 | 70 |
Studies
The one study GlaxoSmithKline leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01424449Depressive Disorder · United Kingdom | 1 | Completed | Jul 2010 | 7 |
How it is read
Names in the registry
- “Aripiprazole”, 81 entries
- “aripiprazole”, 13 entries
- “Aripiprazole IM Depot”, 7 entries
- “Antidepressant + Aripiprazole”, 2 entries
- “Aripiprazole for Injection”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 15 studies
- Depressive Disorder, Major, 10 studies
- Tourette Syndrome, 8 studies
- Autistic Disorder, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.